Activation of human dendritic cells by p-phenylenediamine

被引:35
作者
Coulter, Eve M. [1 ]
Farrell, John [1 ]
Mathews, Karen L. [1 ]
Maggs, James L. [1 ]
Pease, Camilla K. [1 ]
Lockley, David J. [1 ]
Basketter, David A. [1 ]
Park, B. Kevin [1 ]
Naisbitt, Dean J. [1 ]
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
基金
英国惠康基金;
关键词
D O I
10.1124/jpet.106.113803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Exposure to p-phenylenediamine (pPD), a primary intermediate in hair dye formulations, is often associated with the development of allergic contact dermatitis. Such reactions involve activation of the subject's immune system. The aim of these studies was to explore the relationship between pPD oxidation and functional maturation of human monocyte-derived dendritic cells in vitro. Dendritic cells were incubated with pPD and Bandrowski's base (BB) for 16 h, and expression of the costimulatory receptors CD40, CD80, CD83, CD86, and major histocompatability complex class II intracellular glutathione levels and cell viability were measured. In certain experiments, glutathione ( 1 mM) was added to culture medium. Liquid chromatography-mass spectrometry (LC-MS) analysis and exhaustive solvent extraction were used to monitor the rate of [C-14] pPD oxidation and the extent of pPD binding to cellular and serum protein, respectively. Proliferation of allogeneic lymphocytes was determined by incorporation of [H-3] thymidine. Exposure of dendritic cells to pPD (5-50 mu M), but not BB, was associated with an increase in CD40 and MHC class II expression and proliferation of allogeneic lymphocytes. Dendritic cell activation with pPD was not associated with apoptotic or necrotic cell death or depletion of glutathione. Neither pPD nor BB altered dendritic cell expression of CD80, CD83, or CD86. LC-MS analysis revealed pPD was rapidly oxidized in cell culture media to BB. Addition of glutathione inhibited BB formation but did not prevent covalent binding of pPD to dendritic cell protein or dendritic cell activation. Collectively, these studies show that pPD, but not BB, selectively activates human dendritic cells in vitro.
引用
收藏
页码:885 / 892
页数:8
相关论文
共 38 条
[1]   Characterization of the sensitizing potential of chemicals by in vitro analysis of dendritic cell activation and skin penetration [J].
Aeby, P ;
Wyss, C ;
Beck, H ;
Griem, P ;
Scheffler, H ;
Goebel, C .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (05) :1154-1164
[2]   p38 mitogen-activated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene [J].
Aiba, S ;
Manome, H ;
Nakagawa, S ;
Mollah, ZUA ;
Mizuashi, M ;
Ohtani, T ;
Yoshino, Y ;
Tagami, H .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 120 (03) :390-399
[3]   Evaluation of CD86 expression and MHC class II molecule internalization in THP-1 human monocyte cells as predictive endpoints for contact sensitizers [J].
Ashikaga, T ;
Hoya, M ;
Itagaki, H ;
Katsumura, Y ;
Aiba, S .
TOXICOLOGY IN VITRO, 2002, 16 (06) :711-716
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]   Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells [J].
Bour-Jordan, H ;
Salomon, BL ;
Thompson, HL ;
Szot, GL ;
Bernhard, MR ;
Bluestone, JA .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (07) :979-987
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   Thiol antioxidants block the activation of antigen-presenting cells by contact sensitizers [J].
Bruchhausen, S ;
Zahn, S ;
Valk, E ;
Knop, J ;
Becker, D .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (05) :1039-1044
[8]  
CORBETT JF, 1973, J SOC COSMET CHEM, V24, P103
[9]   Impact of cutaneous IL-10 on resident epidermal Langerhans' cells and the development of polarized immune responses [J].
Cumberbatch, M ;
Clelland, K ;
Dearman, RJ ;
Kimber, I .
JOURNAL OF IMMUNOLOGY, 2005, 175 (01) :43-50
[10]  
Curtsinger JM, 1999, J IMMUNOL, V162, P3256